Drug Type Fab fragment |
Synonyms 25.3 monoclonal antibody, Anti-CD11a monoclonal antibody 25.3, Anti-LFA-1 monoclonal antibody + [1] |
Target |
Action antagonists |
Mechanism CD11a antagonists(Leukocyte adhesion glycoprotein LFA-1 alpha antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date France (01 Jan 1997), |
Regulation- |
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | Odulimomab | - |
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Graft vs Host Disease | France | - | 01 Jan 1997 |
| Renal transplant rejection | France | - | 01 Jan 1997 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Delayed Graft Function | Phase 3 | United States | - | |
| Delayed Graft Function | Phase 3 | European Union | - | |
| Delayed Graft Function | Phase 3 | Canada | - |






